• Oltipraz has been shown to inhibit

  2022-02-28

  

  Oltipraz has been shown to inhibit the growth of HCC artemether and is being evaluated in clinical trials as a potential anti-cancer drug for HCC (Mann et al., 2009; Piton et al., 2005; Yates and Kensler, 2007). The present observation that pre-treatment of tumorigenic liver cells with oltipraz cau

• The concentration of rapamycin that gave half

  2022-02-28

  

  The concentration of rapamycin that gave half-maximal induction of the expression of HO-1 and Prx-1 mRNA in normal hepatocytes was 0.05 μM, with maximal induction at about 0.1 μM rapamycin. While, at rapamycin concentrations higher than 0.1 μM, the degree of enzyme induction decreased, elevated expr

• Roflumilast The absence of direct oxidation of Fe by L

  2022-02-28

  

  The absence of direct oxidation of Fe2+ by L1 in experiments in solution would be consistent with the recognized low O2 affinity of sGC. It is known that, in Roflumilast with other hemoproteins, such as globins and heme-containing oxygenases with a Fe2+-proximal histidine linkage, sGC prevents oxid

• br Conflict of interest statement br Acknowledgments

  2022-02-26

  

  Conflict of interest statement Acknowledgments This work was funded in part by a grant from the National Institutes of Health, NIDDK award #DK61425 (to PWS). Introduction The efflux of toxic compounds from the cell by multidrug exporters is an important mechanism for cellular homeostasis a

• Acknowledgments br Introduction Type diabetes

  2022-02-26

  

  Acknowledgments Introduction Type 2 diabetes mellitus (T2DM) is caused by relative insulin deficiency or insulin resistance in peripheral tissues. The clinical management of T2DM is achieved by controlling blood glucose levels. Current therapies available for treatment of T2DM include biguanides

• Data were collected using a Powerlab

  2022-02-26

  

  Data were collected using a Powerlab and Chart 5 software (ADInstruments, Bella Vista, NSW, Australia) and were analysed using GraphPad Prism 5 (GraphPad Software, San Diego, CA). Responses to ghrelin receptor agonists in phenylephrine, methoxamine, endothelin-1, U46619 and 60mM [K+] contracted vess

• br Acknowledgement This work was

  2022-02-26

  

  Acknowledgement This work was supported by National Science Foundation (21475047, 21705051, 21874048), the Science and Technology Planning Project of Guangdong Province (2016B030303010), the Program for the Top Young Innovative Talents of Guangdong Province (2016TQ03N305) and the Foundation for H

• The activation of GPR FFA signaling triggers

  2022-02-26

  

  The activation of GPR40/FFA1 signaling triggers the PLC/PIP2 signaling pathway and results in Ca2+ release from the endoplasmic reticulum (ER). Increased Ca2+ levels may lead to activation of different protein kinases, such as Ca2+/calmodulin-dependent protein kinase type IV, Akt, extracellular sign

• So what makes a FFAR

  2022-02-26

  

  So what makes a FFAR1 agonist different and interesting? As shown in the , the cellular mechanism is different from those of present insulin-releasing pharmacotherapies—namely the secretion initiators (sulphonylureas and meglitinides) and the incretin-based secretion potentiators (glucagon-like pept

• The RAS RAF MEK ERK

  2022-02-26

  

  The RAS/RAF/MEK/ERK pathway (also known as the MAPK/ERK pathway) is one of the most important signaling pathways in PDAC. Activation of the MAPK/ERK pathway promotes PDAC growth and apoptosis resistance in response to gemcitabine [43,44]. We previously demonstrated that inhibition of GPX4 can overco

• In the present study VTE recurrence

  2022-02-26

  

  In the present study, VTE recurrence occurred in a non-cancer patient during edoxaban administration, representing recurrence rates of 1.7% in non-cancer patients and 0.8% in all patients. In a sub-analysis of cancer patients [27] and the main analysis [19] in the HOKUSAI-VTE trial, recurrent VTE oc

• EZH mutations or amplifications have been found in a broad

  2022-02-26

  

  EZH2 mutations or amplifications have been found in a broad spectrum of human cancers including B cell lymphoma, ovarian cancer, breast cancer, melanoma, bladder cancer, gastric cancer, and other cancers (Kim and Roberts, 2016). Given the evidence of EZH2 as a cancer driver, numerous efforts have be

• br Drugs approved or in development

  2022-02-26

  

  Drugs approved or in development To date, three drugs: RAL (MK-0518), EVG (GS-9137) and DTG (GSK1349572) [104], have been approved by the FDA. Their structures are shown in Fig. 5. DTG is under development by GlaxoSmithKline (GSK), and studies have shown DTG to be effective in patients with resis

• br Introduction Sister chromatid cohesion is established dur

  2022-02-25

  

  Introduction Sister-chromatid cohesion is established during DNA replication by a ring-shaped cohesin complex consisting of the core subunits Smc1, Smc3, Scc1, and SA1 or SA2, which recruit regulatory subunits Pds5 (Pds5A/B in vertebrates), Wapl, and Sororin to regulate the association of cohesin

• We found that activator drugs decrease NOsGC protein levels

  2022-02-25

  

  We found that activator drugs decrease NOsGC protein levels in Sf9 cells. This decrease in protein levels is more pronounced for BAY 60–2770 compared to cinaciguat, and more obvious for α1/β1 compared to α2/β1 (see Fig. 2). This led us to hypothesize that the reduction in protein level correlates wi

16660 records 541/1111 page Previous Next First page 上5页 541542543544545 下5页 Last page